SRR3147742
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.490
- INTERFERON_GAMMA_RESPONSE+0.480
- IL6_JAK_STAT3_SIGNALING+0.460
- INTERFERON_ALPHA_RESPONSE+0.420
- ALLOGRAFT_REJECTION+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- TNFA_SIGNALING_VIA_NFKB+0.360
- ANGIOGENESIS+0.330
- XENOBIOTIC_METABOLISM+0.330
- COMPLEMENT+0.310
Top 10 suppressed
- PROTEIN_SECRETION-0.430
- MITOTIC_SPINDLE-0.380
- G2M_CHECKPOINT-0.330
- MYC_TARGETS_V1-0.310
- E2F_TARGETS-0.210
- TGF_BETA_SIGNALING-0.180
- ANDROGEN_RESPONSE-0.170
- UNFOLDED_PROTEIN_RESPONSE-0.160
- PEROXISOME-0.130
- HEME_METABOLISM-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001518_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.905 |
| 2 | TCGA-FD-A5BT-01A-11R-A26T-07 | — | — | 0.891 |
| 3 | 23849071-df2e-4421-b91d-90f66ec2c162 | — | — | 0.883 |
| 4 | MDT-AP-2584 | Med | Medulloblastoma | 0.880 |
| 5 | ERR2598321 | fetal | fetal | 0.876 |
| 6 | TCGA-DK-AA74-01A-11R-A39I-07 | — | — | 0.873 |
| 7 | d6b7de60-321d-4f6d-82e7-3d5e9598462c | — | — | 0.871 |
| 8 | BS_PJPGVD62 | Ependymoma NOS | — | 0.863 |
| 9 | SRR2778056 | — | — | 0.862 |
| 10 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |